Aphria Inc. closed at $19.34 in the latest trading session, marking a +0.78% move from the prior day. This change outpaced the S&P 500's 0.06% loss on the day. At the same time, the Dow lost 0.71%, and the tech-heavy Nasdaq gained 0.76%.
Heading into today, shares of the company had lost 0.21% over the past month, outpacing the Medical sector's loss of 3.68% and lagging the S&P 500's gain of 0.17% in that time.
APHA will be looking to display strength as it nears its next earnings release. In that report, analysts expect APHA to post earnings of -$0.02 per share. This would mark a year-over-year decline of 200%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $139.35 million, up 27.1% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.21 per share and revenue of $529.81 million, which would represent changes of -250% and +30.39%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for APHA. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. APHA currently has a Zacks Rank of #5 (Strong Sell).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Image: Bigstock
Aphria Inc. (APHA) Gains As Market Dips: What You Should Know
Aphria Inc. closed at $19.34 in the latest trading session, marking a +0.78% move from the prior day. This change outpaced the S&P 500's 0.06% loss on the day. At the same time, the Dow lost 0.71%, and the tech-heavy Nasdaq gained 0.76%.
Heading into today, shares of the company had lost 0.21% over the past month, outpacing the Medical sector's loss of 3.68% and lagging the S&P 500's gain of 0.17% in that time.
APHA will be looking to display strength as it nears its next earnings release. In that report, analysts expect APHA to post earnings of -$0.02 per share. This would mark a year-over-year decline of 200%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $139.35 million, up 27.1% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.21 per share and revenue of $529.81 million, which would represent changes of -250% and +30.39%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for APHA. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. APHA currently has a Zacks Rank of #5 (Strong Sell).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 162, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.